Эпилепсия и пароксизмальные состояния (May 2016)
OUR EXPERIENCE IN APPLICATION OF AUTOLOGOUS BONE-MARROW-DERIVED MESENCHYMAL STEM CELLS FOR THERAPY OF PATIENTS WITH SYMPTOMATIC EPILEPSY
Abstract
Abstract: an article presented the data on application of autologous multipotent mesenchymal stem cells (MMSCs) from bone marrow for therapy of 10 patients suffering from drug-resistant symptomatic epilepsy. Intravenous injection of 40.0-101.0Ч106 (mean 68.2± 8,48Ч106) MMSCs endolumbal injection of 2.7-8.0Ч106 (mean 6.34±0.72Ч106) neuroinduced MMSCs did non induced in patients unfovarable reactions an complications. Moreover, during 3-11 months of monitoring 5 of 10 patients demonstrated decrease the frequency or disappearance of seizures, severity the incidence of seizures. 2 patients demonstrated increase of cognitive functions, 2 patients – decrease the level of anxiety. We concluded that application of MMSC-base cellular therapy id safe and enable to facilitate seizure status in patients with drug-resistant symptomatic epilepsy.